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Abstract
MEKK1 is a mitogen-activated protein kinase kinase kinase (MAP3K) that activates the MAPK JNK and is required for
microtubule inhibitor-induced apoptosis in B cells. Here, we find that apoptosis induced by actin disruption via cytochalasin
D and by the protein phosphatase 1/2A inhibitor okadaic acid also requires MEKK1 activation. To elucidate the functional
requirements for activation of the MEKK1-dependent apoptotic pathway, we created mutations within MEKK1. MEKK1-
deficient cells were complemented with MEKK1 containing mutations in either the ubiquitin interacting motif (UIM), plant
homeodomain (PHD), caspase cleavage site or the kinase domain at near endogenous levels of expression and tested for
their sensitivity to each drug. We found that both the kinase activity and the PHD domain of MEKK1 are required for JNK
activation and efficient induction of apoptosis by drugs causing cytoskeletal disruption. Furthermore, we discovered that
modification of MEKK1 and its localization depends on the integrity of the PHD.
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Introduction
MEKK1 isa serine-threonine kinase that activates the c-Jun amino
terminal (N-terminal) kinases (JNK) MAPK module, altering gene
transcription [1].Wehavepreviouslyshownthat MEKK1isessential
for microtubule inhibitor (MTI)-induced JNK activation and
apoptosis through genetic deletion of MEKK1 in chicken bursal B
cells (DT40 cell line) [2]. Given that MTI drugs are important
chemotherapeutic agents involved in treatment of leukemia,
lymphomas, non-small cell lung cancer, breast cancer, testicular
cancer and head and neck cancer, understanding MEKK1 activation
within the context of apoptosis will improve chemotherapy regimens
and outcomes [3,4]. The importance of the MEKK1-dependent
pathway of apoptosis has recentlybeen highlighted by Kan et al.,who
identified MEKK1 as one of the top 50 genes containing somatic
missense and nonsense mutations in a panel of breast, lung, ovarian
and prostate tumors, indicating that impairment of the MEKK1-
dependent apoptotic pathway may enhance tumorigenesis [5].
The extent of MEKK1 involvement in apoptosis by other
mechanisms of cytoskeletal disruption is currently unknown.
Cytochalasin toxins and the protein phosphatase inhibitor okadaic
acid are two examples of drugs that disrupt the cytoskeleton and
cause JNK activation [6,7]. Cytochalasins disrupt actin filament
integrity by capping the barbed end of actin, thus preventing the
addition of G-actin monomers [8]. Okadaic acid inhibits protein
phosphatase 1 and 2A and results in the rapid phosphorylation
and disruption of intermediate filaments [9]. Whether the
MEKK1-dependent apoptotic pathway is involved in the response
to cytochalasins or protein phosphatase inhibition has not been
investigated.
MEKK1 is a 196 kDa protein comprised of a large N-terminal
regulatory region and a C-terminal kinase domain. The N-
terminal region contains features such as a plant homeodomain
(PHD), two overlapping ubiquitin-interacting motifs (UIM), and a
caspase cleavage site [10,11]. Several studies have investigated the
potential functions of different regions of MEKK1. The PHD is a
multifunctional domain that is involved in protein interactions and
is an E3 ligase. An intact PHD is required for interaction with
RhoA, a small GTPase [12]. The PHD is also an E3 ligase for
ERK (Extracellular regulated Kinases) and c-Jun under hyperos-
motic conditions, and is required for MEKK1 autoubiquitination
in overexpression conditions and after CD40 ligand stimulation
[11,13,14,15]. Another MEKK1 region with a potential role in
protein modification by ubiquitin is the UIM. The UIM may aid
in the polyubiquitination of MEKK1, as this domain has been
required for ubiquitination of other UIM-containing proteins [16].
MEKK1 kinase activity has been correlated to apoptosis.
Constitutive kinase activity has been observed when full length
MEKK1 is cleaved at its caspase recognition site, and mutation of
thissite inhibitsapoptosisnormallyseenwithoverexpressionin293T
cells while leaving JNK activation unaffected [17]. In addition,
overexpression of MEKK1 with a mutated kinase domain inhibits
apoptosis by UV light [18]. However, UV-induced apoptosis is
unaffected by the genetic loss of MEKK1, highlighting the difference
between the dominant negative effects caused by overexpression
studies and what occurs under normal physiological conditions [19].
By reconstituting MEKK1-deficient (MEKK1
2/2) cells at more
physiologically relevant levels, we can better differentiate any
dominant negative effects of these mutations from the role that
each may play within the MEKK1-dependent pathway of apoptosis.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17310Here we show that okadaic acid-induced apoptosis and
cytochalasin-induced apoptosis are both impaired by genetic
deletion of MEKK1. This indicates that MEKK1-dependent
apoptosis is not specifically confined to microtubule inhibition,
but may play a broader role in apoptosis activated by the two
other cytoskeletal structures of the cell: actin fibers and
intermediate filaments. Furthermore, we reveal that MEKK1-
deficient murine B cells are also resistant to apoptosis induced by
cytoskeletal disruption, indicating that this phenotype is not
specific to DT40 cells. To determine the role of the various
domains within MEKK1, we created mutations within the PHD,
UIM, caspase cleavage site and the kinase domain, and MEKK1-
deficient cells were reconstituted with each mutant at near
endogenous expression levels. Using this system we found that
the PHD and the kinase domain are required for MEKK1-
dependent JNK activation and apoptosis. Further investigation
indicates that mutation of the PHD results in altered subcellular
localization and reduced levels of basal ubiquitination found on
MEKK1. We also found that while the PHD mutant can be
phosphorylated and activate downstream signals when overex-
pressed at high levels, low level reconstitution of knockout cells
with the PHD mutant results in lack of MEKK1 phosphorylation
after vinblastine treatment. This suggests that the defect in the
PHD mutant resides upstream of MEKK1. Therefore, the
mislocalization of the PHD mutant may interfere with its ability
to interact with upstream proteins.
Results
MEKK1 is required for JNK activation and the apoptotic
response to cytoskeletal disruption
Drugs such as vinblastine, cytochalasin D, and okadaic acid all
induce cytoskeletal disruption and strong MAPK activation. To
determine whether this activation requires MEKK1, DT40
chicken bursal B cell line and its previously generated MEKK1-
deficient (MEKK1
2/2) counterpart were treated with vinblastine,
cytochalasin D and okadaic acid (Figure 1A). Upon treatment with
vinblastine, cytochalasin D and okadaic acid, MEKK1-deficient
cells had undetectable or decreased levels of c-Jun phosphoryla-
tion, whereas ERK and p38 phosphorylation were unaffected by
MEKK1 deficiency. We also noted that total c-Jun levels were
elevated after treatment with these drugs, in a manner partially
dependent on MEKK1. To ensure that the requirement for
MEKK1 in vinblastine-induced apoptosis is not a property
inherent to the chicken DT40 cell line, murine wild type or
MEKK1-deficient bone marrow cells were transformed to create
stable pre-B cell lines. These newly created cell lines were then
analyzed for MAPK activation in response to vinblastine,
cytochalasin D or okadaic acid. Similar to the DT40 MEKK1-
deficient cell line, decreased levels of phosphorylated c-Jun were
observed in the murine MEKK1-deficient line as compared with
the wild type cells (Figure 1B).
Next, we investigated whether apoptosis induced by these drugs
requires MEKK1. Strong DNA laddering was observed in the wild
type DT40 and murine B cell lines in response to vinblastine,
cytochalasin D and okadaic acid (Figure 2A). However, reduced
levels of laddering were seen in both chicken and murine knockout
cell lines. This effect did not appear to be a general defect in
apoptosis, as treatment with the DNA damaging agent etoposide
induced apoptosis in all cell lines (lane Et, Figure 2A). Apoptosis in
response to each drug was then quantified by PI exclusion assay
for each cell line (Figure 2B). In addition, we assessed caspase 3
activity to show that cells were undergoing apoptosis and not just
DNA damage, and found that there is an increased level of active
caspase 3 after each drug treatment in the wild type cells when
compared to the knockout cells, which is consistent with the DNA
laddering and PI exclusion data (Figure 2C). Taken together, these
data indicate that MEKK1 is involved in both JNK activation and
the apoptotic response to a number of cytoskeletal disrupting
agents.
Figure 1. Characterization of MAPK activation in wild type and
MEKK1-deficient cell lines. A. Phosphorylation of c-Jun phosphor-
ylation is defective in the MEKK1
2/2 chicken DT40 cells in response to
cytoskeletal disruption. Wild type (Wt) and MEKK1
2/2 DT40 cells were
left untreated (U) or stimulated with 1 mM vinblastine (Vin), 2 mg/ml
cytochalasin D (Cy), and 90 nM okadaic acid (OA) for four hours, lysed
in modified RIPA buffer and run on an SDS-PAGE gel to compare wild
type and knockout cell lines. Western blot membranes were probed
for phosphorylated and total c-Jun, ERK and p38. B. Phosphorylation of
c-Jun is defective in MEKK1
2/2 murine pre-B cells in response to
cytoskeletal disruption. Wild type (Wt) and MEKK1
2/2 pre-B murine
cells were stimulated with 1 mM vinblastine, 2 mg/ml cytochalasin D,
and 90 nM okadaic acid for four hours, lysed in modified RIPA buffer
and run on an SDS-PAGE gel. Membranes were probed for
phosphorylated and total c-Jun, ERK and p38. b-tubulin is used as
loading control.
doi:10.1371/journal.pone.0017310.g001
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modification and localization, but not induction of
downstream signaling
To identify specific domains of MEKK1 required for apoptosis
in response to cytoskeletal disruption, mutations were created
within different domains of MEKK1 (Figure 3A). Two mutations
were introduced into the PHD domain of rat MEKK1 (
Cys478
Ala
and
Cys481
Ala; MutP); these mutations have been shown to disrupt
the zinc finger structure and destroy its E3 ligase function [11].
The putative UIM of MEKK1 (amino acid 1176 to 1191) was
deleted to create delU. The critical lysine residue within the kinase
active site of MEKK1 was mutated to methionine (1265
K to
1265
M; MutK) to disrupt activation of the kinase domain. To
determine if caspase cleavage of MEKK1 is required for apoptosis
in our system, we mutated the aspartic acid residues in the caspase
recognition site of rat MEKK1 to glutamate (
878DTLD
881 to
ETLE) to create MutC; the orthologous caspase mutation of
murine MEKK1 has been reported to render murine MEKK1
resistant to cleavage at this site [17,20].
Each MEKK1 mutant was overexpressed in 293T cells in the
highly expressing pApuro vector and analyzed via western blot to
check for protein expression. As seen in Figure 3B, the mutant
constructs expressed at the proper MEKK1 protein size of
196 kD. We also noted that normally MEKK1 appears to be
highly modified as apparent by the presence of multiple MEKK1
bands (Figure 3B), but among our mutations, the PHD mutant was
noticeably lacking this modification.
Because overexpression of MEKK1 causes JNK activation and
downstream c-Jun phosphorylation, we next investigated the
effects of each mutant in downstream signaling through JNK in
our 293T overexpression system. Each mutant could still initiate
Figure 2. Detection of apoptosis after cytoskeletal disruption in wild type and MEKK1-deficient cell lines. A. DNA laddering is
significantly decreased in the MEKK1
2/2 DT40 and murine pre-B cell lines upon treatment with vinblastine, cytochalasin D, and okadaic acid, whereas
the response to etoposide is unchanged. Wild type (Wt) or MEKK1
2/2 DT40 cell lines were treated with 1 mM vinblastine (Vin), 2 mg/ml cytochalasin D
(Cy), 90 nM okadaic acid (OA), or DMSO (DM) for six hours or 25 mM etoposide (Et) for four hours. After treatment, each line was assessed for the
presence of DNA laddering. Wild type (Wt) or MEKK12/2 murine cell lines were treated with the same concentration of these drugs for nine hours
and DNA laddering was assessed. B. Apoptosis was quantified by propidium iodide exclusion assay. Wild type (Wt) or MEKK1
2/2 DT40 were treated
with 1 mM vinblastine (Vin), 2 mg/ml cytochalasin D (Cy) for DT40 cells, 90 nM okadaic acid (OA), DMSO (DM) or 15 mM etoposide (Et) for 12 hours.
Wild type (Wt) or MEKK1
2/2 murine pre-B cells were treated with 1 mM vinblastine (Vin), 4 mg/ml cytochalasin D (Cy) for DT40 cells, 90 nM okadaic
acid (OA), DMSO (DM) or 15 mM etoposide (Et) for 14 hours. After treatment, the percentage of apoptotic cells was assessed by measuring
fluorescence of the sub-diploid population using flow cytometry. C. Caspase 3 activation is abrogated in the MEKK1
2/2 cell lines after cytoskeletal
disruption. DT40 and MEKK1
2/2 cells (left panel) were treated with 1 mM vinblastine and 2 mg/ml cytochalasin for four hours and 90 nM okadaic acid
for six hours. Murine wild type and MEKK1
2/2 pre-B cells (right panel) were treated with 1 mM vinblastine and 2 mg/ml cytochalasin and 90 nM
okadaic acid for six hours. Cell lysates were used to determine the catalytic activity of caspase 3.
doi:10.1371/journal.pone.0017310.g002
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the anticipated exception of the kinase mutation (Figure 3B).
To determine the cellular localization of each mutant, we
expressed each in HeLa cells and visualized localization with
indirect immunofluorescence (Figure 3C). The localization of
MEKK1 has been well characterized by immunofluorescence. As
previously published and in our system, MEKK1 was expressed
diffusely through the cytosol and in small punctuate structures
[21]. The UIM, caspase 3 and kinase dead mutants were
expressed in a manner similar to wild type MEKK1, but the
PHD mutant was located expressly in large, distinct punctuate
structures. To ensure that the change in the PHD mutant
localization was not due to enhanced lysosomal degradation,
indirect immunofluorescence was performed with both MEKK1
and LAMP1, a marker for lysosomes (Figure 3D). We found that
neither wild type MEKK1 nor the PHD mutant significantly
colocalize with lysosomes. To investigate whether the subcellular
localization of MEKK1 or any of the MEKK1 mutants change
upon treatment with MTIs, transfected HeLa cells were treated
with vinblastine and subjected to immunofluorescence as before
Figure 3. Creation and characterization of MEKK1 mutations. A. Schematic diagram of MEKK1, and MEKK1 mutants illustrating the plant
homeodomain (MutP), the ubiquitin-interacting motif (delU), the kinase domain (MutK) and the putative caspase cleavage site (MutC). Arrows
indicate the mutations created within each domain. B. Proper protein expression and determination of downstream signaling via c-Jun
phosphorylation after overexpression of each mutation. Each mutant was transiently transfected into 293T cells in the highly expressing pApuro
construct. Cell lysates were run on SDS-PAGE, western blots were performed and MEKK1 was detected with aMEKK1 C-22. Blots were next probed
with total c-Jun, which recognizes both the dephosphorylated and phosphorylated forms of c-Jun. C. Cellular localization of each mutant. HeLa cells
were transfected with pApuro MEKK1, MutP, delU, MutK or MutC and stained with DAPI (nucleus) and aMEKK1 C-22 antibody (MEKK1) after 24 hours
of transfection. D. The PHD mutant does not colocalize with lysosomes to a greater extent than wild type MEKK1. HeLa cells were transfected with
flag-MEKK1 or flag-MutP and stained with DAPI, M2 aflag (MEKK1) and LAMP1 (lysosomes) after 24 hours. MEKK1 was detected with mouse aFITC and
LAMP1 with rabbit aTRITC. E. The PHD mutant localization is not altered by vinblastine treatment. HeLa cells were transfected with pApuro MEKK1,
MutP and MutK. After 24 hours cells were treated with vinblastine for one hour. MEKK1 was visualized with aMEKK1 C-22 antibody and nuclei
visualized with DAPI.
doi:10.1371/journal.pone.0017310.g003
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and the kinase dead mutant changed localization, from diffuse/
punctate in the periphery to aggregates in the peri-nuclear region.
However, the appearance and location of the PHD mutant did not
change after vinblastine treatment.
The PHD mutant exhibits decreased ubiquitination
The difference in subcellular localization between wild type
MEKK1 and the PHD mutant prompted us to investigate possible
differences in post-translational modifications between the two
proteins. Deak et al. have previously shown that overexpressed
MEKK1 is auto-phosphorylated [22]. We hypothesized that the
modified form of MEKK1 that we see in our assays (Figure 3B,
MEKK1 upper bands) may be due to phosphorylation of multiple
sites in MEKK1. To test this hypothesis, we set out to determine
whether the loss of basal modification on the PHD mutant (lack of
upper band in MutP lane, Figure 3B) correlated with the loss of
MEKK1 phosphorylation. We found that both wild type MEKK1
and the PHD mutant were phosphorylated in the kinase domain
when overexpressed (Figure 4A). Furthermore, treatment of DT40
cells with calf-alkaline phosphatase shifted the size of vinblastine
treated (and therefore phosphorylated), but not untreated DT40
cells (Figure 4B), indicating that the observed basal modification
on endogenous MEKK1 is not phosphorylation. However, the
PHD also has intrinsic E3 ligase activity and destroying this
domain results in defective auto-polyubiquitination [14]. There-
fore, it is possible that the PHD is required for ubiquitination of
MEKK1. Thus, we asked whether this modification can be due to
ubiquitination. To determine if MEKK1 is ubiquitinated, we
questioned whether the modification found on MEKK1 would be
stabilized by a deubiquitinase inhibitor, such as N-ethylmaleimide
(NEM). We found that the high molecular weight band of
MEKK1 is enhanced by treatment of cell lysates with NEM when
compared to untreated cells (Figure 4C). Finally, overexpression
and immunoprecipitation of empty vector, MEKK1 or the PHD
mutant followed by detection with ubiquitin antibody indicate that
only wild type MEKK1 is strongly ubiquitinated (Figure 4D).
These biochemical assays indicate that while the PHD mutant can
be phosphorylated when overexpressed, modification by ubiquitin
is abrogated in the PHD mutant.
Endogenous level reconstitutions of MEKK1-deficient
cells indicate that the PHD and the kinase domain of
MEKK1 are required for JNK activation after cytoskeletal
disruption
To determine if any candidate domains were required for JNK
activation inresponseto cytoskeletal disrupting drugs,eachMEKK1
mutant was expressed in MEKK1-deficient DT40 cells. However,
because the increased JNK and ERK activation caused by MEKK1
overexpression may interfere with the response to cytoskeletal
disruption, we sought to first establish a low-level expression system
using the pBabe retroviral vector, which would not significantly
increase JNK or ERK activation in resting cells. After retroviral
infectionandselectionwithpuromycin,thepolyclonalpopulationsof
knockout cells reconstituted with MEKK1 were checked for
expression levels in comparison to the DT40 cell line by western
blot (Figure 5A, left panel). Murine MEKK1-deficient cells were not
used due to inherent puromycin resistance that prevented the
analysis of puromycin-selected polyclonal populations. While the
level of expression was slightly higher in the reconstituted cell line, it
was far less than traditional overexpression vectors. Furthermore, all
reconstituted cells are shown to have relatively equivalent levels of
MEKK1 mutant expression (Figure 5A, right panel). Additionally,
reconstitution of the MEKK1-deficient cells did not show the
increased basal MAPK activity seen when MEKK1 is overexpressed
in the 293T system (Figure 5B, 5C, 5D).
Next, the MEKK1-deficient reconstituted cells were treated
with cytoskeletal disrupting drugs, and the effects of these
mutations on downstream signaling were determined. Cytoskeletal
structure was disrupted with either 1 mM vinblastine, 2 mg/ml
cytochalasin D or 90 nM okadaic acid for 4 hours and
phosphorylation of c-Jun was analyzed by western blot. Robust
phosphorylation of c-Jun was observed in the MEKK1
Wt,
MEKK1
mutC and MEKK1
delU reconstituted cell lines, but
MEKK1
mutP, MEKK1
mutK (MEKK1-deficient cells reconstituted
with each mutation are referred to as MEKK1
mut) and MEKK1-
deficient cell lines demonstrate abrogated c-Jun phosphorylation
in response to cytoskeletal disruption. Total levels of c-Jun were
also analyzed and levels were enhanced after cytoskeletal
disruption (Figure 5B, C and D). This increase appears to be
partially dependent on MEKK1 activation, but the extent of
MEKK1 dependence seems to vary depending on the stimuli.
After determining that the MEKK1
mutP cell line exhibits
decreased amounts of c-Jun phosphorylation after cytoskeletal
disruption, the cause of this defect was investigated. We had already
observed that MEKK1
mutP can activate downstream signaling
when overexpressed (Figure 3B), so we hypothesized that the defect
in activation of the MEKK1
mutP cell line (where MEKK1 is
expressed at near endogenous levels and therefore cannot auto-
activatedownstreamsignaling) liesinreceivingupstream signals. To
test this we investigated whether MEKK1 can become phosphor-
Figure 4. Identifying the post-translational modifications of
the MEKK1 protein. A. The PHD mutant can be phosphorylated.
Vector, wild type flag-MEKK1 and flag-PHD mutant (mutP) were
transfected into 293T cells and immunoprecipitated with aflag M2
conjugated beads. Membranes were probed with total or phospho-
MEKK1. B. CIP treatment does not affect basal MEKK1 modification, but
does shift the molecular weight of vinblastine treated (phosphorylated)
endogenous MEKK1. DT40 cells were treated with vinblastine for six
hours and lysates were immunoprecipitated with aMEKK1. Half of each
lysate was treated with calf alkaline phosphatase and all were incubated
at 37u, run on SDS-PAGE gel and membranes were probed with
aMEKK1. C. Inhibition of de-ubiquitinating enzymes via N-ethylmalei-
mide (NEM) stabilizes the higher molecular weight form of MEKK1. Wild
type DT40 cells were lysed in modified RIPA. Lysates were treated with
or without 20 mM NEM for 30 minutes at room temperature. Lysates
were run on SDS-PAGE and probed with a MEKK1. D. MEKK1 is
ubiquitinated whereas the PHD mutant is not. 293T cells were
transiently transfected with vector, flag-MEKK1 or mutP. Cell lysates
were immunoprecipitated with flag-conjugated beads, run on an SDS-
PAGE gel and probed with aubiquitin or aMEKK1.
doi:10.1371/journal.pone.0017310.g004
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kinase domain, which also corresponds to activation of this protein
as a kinase [15,23]. We treated knockout cells reconstituted with
MEKK1 mutant cell lines with vinblastine and subjected the lysates
to immunoprecipitation, western blot, and detection with a
phosphorylation-specific antibody indicative of MEKK1 activation
[23]. We determined that within 2 hours of vinblastine treatment
MEKK1
Wt, MEKK1
delU and MEKK1
mutC are active as indicated
by auto-phosphorylation, whereas MEKK1
mutP and MEKK1
mutK
are not (Figure 6), indicating that mutation of the PHD results
in an inability to be activated under physiologically relevant
conditions.
Because MEKK1 can degrade ERK via the activity of the PHD
under conditions of osmotic stress, and ERK activation is generally
linked to survival signals, ERK levels and its activation were also
analyzed after cytoskeletal disruption [11,13]. As with the parental
DT40 and MEKK1-deficient cells, vinblastine treatment did not
change the total level of ERK (Figure 7A), and ERK phosphor-
ylation was undetectable. While ERK was activated from
30 minutes to six hours after cytochalasin D and okadaic acid
treatment, no differences were seen between the wild type,
knockout and reconstituted lines (Figure 7, B and C).
Figure 5. The PHD and kinase domains are essential for MEKK1-dependent JNK activation. A. Expression of mutations in relation to
endogenous MEKK1. HA-His-tagged pBabeMEKK1 was introduced into MEKK1
2/2 (2/2) DT40 cells by retroviral infection (reconstituted cells are
referred to here as M-
Wt and MEKK1
Wt in the text), selected with puromycin and protein levels were assessed by western blot probed with aMEKK1
(left panel). The size difference between His-HA-tagged and endogenous MEKK1 is indicated. Each mutation was introduced into MEKK1
2/2 cells and
expression was compared (right panel). Reconstituted cell lines are referred to as M-
mutation within each figure. B. The PHD and kinase domain are
required for c-Jun phosphorylation after vinblastine stimulation. Reconstituted cell lines were stimulated with 1 mM vinblastine (Vin) for four hours
and lysed in modified RIPA. Phosphorylated c-Jun, total c-Jun and b-tubulin were assessed by western blot. C. There is a decreased amount of c-Jun
phosphorylation in the MEKK1
2/2, PHD and kinase domain mutant cell lines after cytochalasin D treatment. Phosphorylation of c-Jun and total c-Jun
levels of each reconstituted cell line was assessed by western blot after four hours of 2 mg/ml cytochalasin D (Cy) treatment. D. There is a decreased
amount of c-Jun phosphorylation in the MEKK1
2/2, PHD and kinase domain mutant cell lines after okadaic acid treatment. Phosphorylation of c-Jun
and total c-Jun levels of each reconstituted cell line was assessed by western blot after four hours of 90 nM okadaic acid (OA) treatment.
doi:10.1371/journal.pone.0017310.g005
Figure 6. MEKK1
mutP is not phosphorylated in the activation
loop after vinblastine treatment. MEKK1
2/2, MEKK1
Wt, MEKK1
mutP
or MEKK1
mutK (left panel) and MEKK1
delU, MEKK1
mutC (right panel) cell
lines were treated with 1 mM vinblastine for 2 hours. Cell lysates were
immunoprecipitated with aHA-agarose, run on SDS-PAGE gel and
probed with aphospho-MEKK1 followed by detection of total MEKK1
with aMEKK1 C-22.
doi:10.1371/journal.pone.0017310.g006
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apoptosis after cytoskeletal disruption
To identify the domains of MEKK1 required for apoptosis
inducedbycytoskeletaldisruption,DT40reconstitutedcelllineswere
stimulated with vinblastine, cytochalasin D or okadaic acid, and
apoptosis was analyzed via DNA laddering (Figure 8B, C and D).
While wild type DT40 cells, MEKK1
Wt, MEKK1
delU and
MEKK1
mutC reconstituted cells exhibited DNA laddering after
cytoskeletal disruption, the MEKK1
mutP and MEKK1
mutk reconsti-
tuted cells were resistant to apoptosis.This defectinapoptosiswas not
the resultof general resistanceto apoptosis, as each cellline could still
induce apoptosis in response to etoposide, a MEKK1-independent
stimulus (Figure 8A). The response to cytoskeleton disruption was
then quantified by PI exclusion assay, which is consistent with the
DNA laddering results (Figure 9A). Our results show that MEKK1,
MEKK1
delU and MEKK1
mutC induced apoptosis at levels similar to
wild type cells, but therewas no significant increaseinthe percentage
of apoptotic cells in the knockout, MEKK1
mutK or MEKK1
mutP cell
lines with vinblastine, cytochalasin D or okadaic acid (Figure 9A
panelsI,II,III,respectively).Vinblastine-inducedapoptosishasbeen
shown to activate the caspase pathway and Figure 9B shows that
caspase3activityisalsosignificantlyreducedintheMEKK1
mutP and
MEKK1
mutK as compared to the MEKK1
Wt,M E K K 1
delU and
MEKK1
mutC reconstituted cells after treatment with vinblastine,
cytochalasin D or okadaic acid (Figure 9B panels I, II, III,
respectively).
Discussion
MTIs such as vinblastine are important chemotherapy drugs,
but the mechanism by which these drugs initiate apoptosis is not
clear. We have previously shown that MEKK1 is required for
apoptosis in DT40 B cells in response to MTIs [2]. However, the
requirement of MEKK1-dependent apoptosis upon treatment
with other toxic agents had not been thoroughly investigated. Here
we have shown that MEKK1 activation is involved in apoptosis
induced by general cytoskeleton disruption and that a functional
PHD and kinase domain are required to induce apoptosis.
The requirement of MEKK1 for JNK activation in response to
MTIs has been consistent in published data. However, in different
studies the outcome of JNK activation after treatment with
microtubule inhibitors has been attributed to two opposing effects,
either enhanced apoptosis or increased cell survival Our previous
study with DT40 cells indicates that MEKK1 is required for JNK
activation and apoptosis after vinblastine stimulation. However, it
has been published that treatment of Mekk1
2/2 ES cells with the
MTIs nocodazole or taxol result in defective JNK activation but
somewhat increased sensitivity to apoptosis [6,19,24]. Whether
this discrepancy was due to a cell-specific effect or a species-
specific effect was unclear. Here we report that vinblastine-
stimulated apoptosis is MEKK1-dependent in both chicken DT40
and murine B cell lines, indicating that the discrepancy is not
specific to chicken cells.
Figure 7. The PHD and kinase domains of MEKK1 are not essential for maximal ERK activation. A. ERK is not activated or degraded after
vinblastine treatment. Wild type, knockout and MEKK1-reconstituted MEKK1
2/2 cells were treated with 1 mM vinblastine for four hours and total ERK
or b-tubulin were assessed by western blot. B. Activation of ERK by cytochalasin treatment is not MEKK1-dependent. Cell lines were treated with
2 mg/ml cytochalasin D for two hours and phosphorylated and total ERK were evaluated by western blot. C. Activation of ERK by okadaic acid
treatment is not MEKK1-dependent. Phosphorylation of ERK and total ERK were determined by western blot after treatment with 90 nM okadaic acid
for four hours. b-tubulin was used as a loading control.
doi:10.1371/journal.pone.0017310.g007
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this apoptotic pathway, we created mutations in characterized
domains within MEKK1 and reconstituted MEKK1-deficient
DT40 cells at near endogenous levels, which would not
independently activate MAPK pathways and confound our results.
By expressing each mutation at levels that do not increase JNK or
ERK activation in resting cells, we were able to clarify which
domains of MEKK1 are actually involved in carrying out
apoptosis after cytoskeletal disruption. Among the four mutations
in our study, the caspase cleavage and UIM deletion mutants were
able to compensate for MEKK1 in our readout assays, indicating
that these domains are unnecessary for MEKK1 function after
cytoskeletal disruption. The caspase recognition site has been
postulated to be required for the release of the kinase domain from
a particulate fraction to a soluble cytoplasmic fraction, which was
shown to be necessary for the pro-apoptotic function of MEKK1
in an overexpression system [21]. Previously, in a 293T
overexpression system, Widmann et al. showed that mutation of
the caspase 3 recognition site rendered murine MEKK1 less
effective in inducting apoptosis caused by overexpression of
MEKK1 [17]. However, in our system the orthologous mutation
in the rat MEKK1 caspase site is inconsequential for vinblastine-
induced JNK activation and apoptosis (Figure 5 and 9). As seen in
Figures 8 and 9, reconstituted DT40 cells expressing the
MEKK1
mutc at near endogenous levels undergo apoptosis after
treatment with cytoskeletal disrupting drugs. In addition, down-
stream signaling as detected by c-Jun phosphorylation is
unaffected (Figure 5B, C and D). There are a number of possible
explanations for this apparent discrepancy. First, in our system
with treatment of cytoskeletal disrupting drugs the cytoskeleton
structure is already disrupted and MEKK1 moves to a region near
the nucleus (Figure 3E). This movement is also detected by
antibodies to the N-terminal flag tag on flagMEKK1 (data not
shown); therefore MEKK1 cleavage and kinase domain release
from the particulate fraction are not necessary for MEKK1
movement after cytoskeletal disruption. It is also possible that in
the 293T overexpression system used by Widmann et al., the
caspase cleavage mutant is highly overexpressed and therefore
could function in a manner different than endogenous-level
MEKK1 [17]. Additionally, our studies do not rule out the
possibility of alternative cleavage sites in the chicken B cells that
could compensate for mutation of the characterized caspase
cleavage site.
Deletion of the UIM domain also does not affect MEKK1-
dependent JNK activation, apoptosis or modification in our B cell
reconstitution system. UIM regions contained in other proteins
have been shown to directly interact with ubiquitin and can
enhance the ubiquitination of these UIM-containing proteins
[16,25]. For example, auto-ubiquitination of TRAC-1 requires
both its RING and UIM domains, as point mutations in either
domain reduce the amount of ubiquitinated TRAC-1 [25].
MEKK1 is also autoubiquitinated when overexpressed in
conjunction with ubiquitin. Ubiquitination of endogenous
MEKK1 occurs after CD40 stimulation composed of K63-linked
(activation related) ubiquitin chains [15,23,26]. However, the
function of MEKK1 ubiqutination has not been further
investigated. We hypothesized that the UIM region was required
for either monoubiqutination or polyubiquitination of MEKK1,
and through these actions, it can influence MEKK1 activation.
The previous study regarding the function of the UIM within
MEKK1 used a 35 kDa isolated region of MEKK1 containing the
UIM linked to yellow fluorescent protein (YFP) to examine its
Figure 8. The PHD and kinase domains are required for vinblastine induced apoptosis. A. MEKK1
2/2 DT40 cells reconstituted with MEKK1
or mutations thereof all initiate apoptosis in response to etoposide. Each reconstituted cell line was treated with 25 mM etoposide (Et) for four hours
and subjected to DNA laddering assay. B. MEKK1
2/2 cell lines reconstituted with MEKK1 containing the PHD or kinase mutations do not result in DNA
fragmentation after vinblastine treatment. Each reconstituted cell line was treated with 1 mM vinblastine (Vin) for six hours and subjected to a DNA
laddering assay. C. There is a defective the DNA laddering response in the PHD or kinase domain mutant cell lines after cytochalasin D treatment.
Reconstituted cell lines were treated with 2 mg/ml cytochalasin D (Cy) for six hours and subjected to DNA laddering assays. D. There is a defective the
DNA laddering response in the PHD or kinase domain mutant cell lines after okadaic acid treatment. Reconstituted cell lines were treated with 90 nM
okadaic acid (OA) for six hours and subjected to DNA laddering assays.
doi:10.1371/journal.pone.0017310.g008
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other UIM regions such as Hrs or epsin were ubiquitinated, the
MEKK1 UIM region was unable to bind ubiquitin. The lack of
interaction of MEKK1 UIM and ubiquitin in this study could
have been due to the fact that the overall tertiary structure of
MEKK1 is necessary for the function of the MEKK1 UIM, so in
our experiments, we deleted the entire 16 amino acid region
containing the UIM while retaining all other domains of full length
MEKK1. However, the UIM deletion mutant of MEKK1 was
able to function similarly to wild type MEKK1, indicating this
domain is unnecessary for MEKK1-dependent cell death by
cytoskeletal disruption. We determined that the UIM mutant can
be auto-ubiquitinated in an overexpression system to the same
extent as wild type MEKK1 (data not shown). Our data,
combined with the YFP-UIM data, suggests that while the
consensus sequence for a UIM region is present in MEKK1, this
domain is not absolutely required for kinase activation or
autoubiquitination of MEKK1.
In this study, JNK activation correlates with apoptosis after
treatment with cytoskeletal disrupting drugs. In our MEKK1-
deficient cells, JNK activation is abrogated, and reconstitution of
these cells with MEKK1 restores JNK activation. Therefore, JNK
activity is used as an indicator of MEKK1 activity. In this paper
and our previous study, MEKK1-dependent JNK activation
correlates strongly with apoptosis, and previous reports have
shown that absence or inhibition of JNK resulted in decreased
levels of apoptosis with vinblastine treatment [28,29]. We also
show that the JNK substrate c-Jun upregulation after vinblastine
treatment is partially dependent upon MEKK1, and upregulation
of c-Jun has been shown to contribute to vinblastine-induced
apoptosis [30]. The duration of JNK activation may also be
important for inducing apoptosis. Here, vinblastine, cytochalasin
Figure 9. Quantification of apoptosis by propidium iodide incorporation and caspase 3 activity. A. In the MEKK1
mutP and MEKK1
mutK cell
lines the percentage of apoptotic cells does not significantly increase after cytoskeletal disruption. To quantify the levels of DNA fragmentation,
propidium iodide staining was analyzed by flow cytometry. Cell lines were treated with 1 mM vinblastine (panel I), 2 mg/ml cytochalasin D (panel II) or
90 nM okadaic acid (panel III) for twelve hours and the percentage of apoptotic cells were determined by measuring fluorescence lower than the
diploid population using CellQuest software. B. Caspase 3 is not activated in the MEKK1
mutP or MEKK1
mutK cell lines after cytoskeletal disruption.
Caspase 3 activity was determined after four hours of treatment with 1 mM vinblastine (I), 2 mg/ml cytochalasin D (II) or 90 nM okadaic acid (III)
treatment. Cell lysates were used to determine the catalytic activity of caspase 3 by using the colorimetric substrate Ac-DEVD-pNA and measured at
405 nM.
doi:10.1371/journal.pone.0017310.g009
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dependent JNK activation until cell death, while activation of
other potential MEKK1 targets such as ERK, p38 or NF-kB are
unaffected by the loss of MEKK1 [2]. In other systems, prolonged
JNK activation has been linked to enhancing apoptosis [1]. For
example, short term activation of JNK after TNFa stimulation
results in proliferation and survival, but TNFa treatment with
conditions resulting in prolonged JNK activation promotes cell
death [31,32]. Given that the kinase activity of MEKK1 is
required for cell death, JNK is robustly activated by MEKK1, and
that prolonged JNK activation has been tied to cell death, it is
strongly suggested that JNK activation plays a significant role in
MEKK1-dependent apoptosis in response to cytoskeletal disrupt-
ing drugs.
Mutations of both the PHD and kinase domains reduce JNK
activation and abrogate MEKK1-dependent apoptosis after
cytoskeletal disruption. While disrupting the PHD domain at
physiologically relevant levels clearly results in defective JNK
activation and apoptosis (Figures 5 and Figure 8–9, respectively), we
andothershaveshownthatoverexpressingMEKK1witha mutated
PHD at high levels results in activation of and possibly enhanced
downstream signaling [14]. Therefore, it is possible that the PHD is
required for specific upstream interactions that are unnecessary in
overexpression systems. There is also evidence that mutation of the
PHD results in the inability to interact with MEKK1 activating
proteins such as RhoA or TRAF2, which interact with MEKK1
after activin or CD40 ligand stimulation [12,15]. However in our
system these particular interactions do not appear to be required for
the MEKK1-dependent apoptosis. Overexpression of a dominant
negative RhoA in 293T cells did not inhibit vinblastine-induced
JNK activation. Furthermore, TRAF2-deficient mouse embryonic
fibroblasts (MEFs) exhibit normal JNK activation after vinblastine
treatment, indicating they are not upstream of MEKK1 in the
vinblastine-activated pathway (data not shown).
Other functions for the PHD within MEKK1 have been
proposed. Lu et al. and Xia et al. have shown that the PHD is
required for MEKK1 to ubiquitinate and degrade ERK and c-Jun
under conditions of osmotic stress [11,13]. Although we can repeat
this data with our system when under hyperosmotic conditions (data
not shown), after vinblastine treatment ERK and c-Jun are not
degraded (Figure 7and Figure 5 B,Cand D).Whilewe donot detect
ubiquitinationanddegradationofMEKK1substrates,wedoseethat
MEKK1
mutP lacks the modification normally seen with MEKK1
(Figure3B and Figure 5A).Wehave performed multiple biochemical
assays which indicate this modification is ubiquitin (Figure 4C and
D). Since ubiquitination has been reported to affect protein
interactions as well as protein sorting and trafficking, we hypothe-
sized that decreased ubiqutination of the PHD mutant results in the
mislocalization of MEKK1. The localization of MEKK1 has been
well characterized by immunofluorescence [21]. Our data confirms
that MEKK1 is expressed diffusely through the cytosol and in small
punctuate structures (Figure 3C). However, the PHD mutant
presents a strikingly different localization than wild type MEKK1.
We further illustrate that this localization is not due to enhanced
lysosomal degradation by immunofluorescence with a lysosome
marker, LAMP1 (Figure 3D). The LAMP1 protein associates with
late endosomes/lysosomes and when detected in conjunction with
MEKK1 or the PHD mutant, we did not observe a difference in co-
localization. Interestingly, both wild type MEKK1 and kinase dead
mutant shift localization to near the nucleus after vinblastine
treatment, (Figure 3E), whereas the PHD mutant does not change
itscellularlocalizationpatternaftercytoskeletaldisruption.Thus,this
alteration in cellular localization appears to be independent of
MEKK1 activity, supporting the possibility that mutation of the
PHD results in aberrant localization due not to impaired activation
after vinblastine treatment, but from a change in initial protein
interactions. Since ubiquitination can alter protein localization, lack
of ubiquitination may explain mislocalization caused by mutation of
the PHD and the importance of the PHD for interaction with many
proteins, but this requires further investigation.
Finally, we have shown that MEKK1-dependent apoptosis
occurs not only by MTIs, but also in apoptosis induced by actin
disruption and protein phosphatase inhibition (Figure 2). Actin
disruption can activate ERK and JNK and induce apoptosis in
lymphocytes, airway epithelial cells and various cancer cell lines
[33,34,35]. Okadaic acid and another protein phosphatase
inhibitor, cantharidin, also induce apoptosis in lymphocytes and
cause extensive activation of the JNK, ERK and p38 MAPK
pathways [36,37]. While cytochalasins, protein phosphatase
inhibitors and microtubule inhibitors have diverse effects upon
cells, maximal JNK activation and apoptosis are only triggered in
the presence of MEKK1. In this study we have shown that
effective treatment with three different classes of drugs requires
MEKK1. Therefore, screening more drug panels for prolonged
MEKK1/JNK activation may result in the identification of novel
chemotherapeutics or combinations of existing drugs.
It is critical to understand the MEKK1-dependent apoptotic
pathway, as vinblastine and other vinca alkaloid family members
play a key role in chemotherapy for lymphomas, leukemia, breast,
testicular and some non-small cell lung cancers. To date, most
recommended chemotherapy regimens use combinations of drugs,
and understanding how MEKK1 activity is affected by these drug
combinations could enhance the efficacy of therapy. For example,
drug combinations that result in higher MEKK1 activity may be
desirable for treatment of leukemia and lymphoma, which induce
rapid cell death via MEKK1. Further study of the MEKK1-
dependent pathway of apoptosis will be useful in targeting new
molecules for cancer therapy, and for understanding resistance to
cytoskeletal disruption-induced apoptosis.
Materials and Methods
Ethics Statement
The human cell lines used in this study are well established and
were handled under the biosafety level 2 standards established by
UCLA.ThemurineBcelllineswerecreatedfromMEKK1wildtype
and knockout murine bone marrow, shipped to us from the
laboratory of Bing Su at Yale University, using the standard p210
BCR-ABL retroviral transformation protocol complicit with biosafety
level 2 standards. As this study did not require direct work with mice
or primary human tissues, no additional approval was necessary.
Plasmids
PBabe ratMEKK1 containing a hemagglutinin (HA) and a His
tag was generated by digesting pskMEKK1+EcoR1 plasmid with
EcoR1 and subcloning into the Maloney Murine Leukemia Virus-
based retroviral vector pBabepuro vector. PApuro ratMEKK1
was generated by excising MEKK1 from the pCEP4HAMEKK1
vector and this insert was subcloned into the chicken actin
promoter expression vector pApuro between Spe1 and Sal1
restriction enzymes sites in the polylinker. MEKK1 mutations
were created by PCR mutagenesis. N-terminal flag-tagged
MEKK1 was generated by subcloning into the CMV-flag
construct provided generously by the lab of Steve Smale.
Reagents
Vinblastine sulfate was acquired from MP Biomedicals (Solon,
OH). Cytochalasin D and okadaic acid were obtained from
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Roche Molecular Biochemicals (Indianapolis, IN). Lipofectamine
2000 was purchased from Invitrogen. Anti-HA Y-11 and Anti-
MEKK1 were purchased from Santa Cruz Biotechnologies (Santa
Cruz, CA). Anti-phosphorylated c-Jun, anti-c-Jun, anti-phosphor-
ylated ERK1/2 and anti-ERK1/2 were purchased from Cell
Signaling Technologies (Beverly, MA). Anti-HA was purchased
from Covance (Cumberland, VA). Anti-b tubulin, aflag (M2),
aflag-conjugated agarose beads and EZ view HA-conjugated
agarose beads were obtained from Sigma-Aldrich (Saint Louis,
MO). Protein G sepharose fast flow 4 was purchased from GE
Healthcare Biosciences (Piscataway, NJ). The phospho-MEKK1
antibody was generously donated by Dr. Ewen Gallagher. This
antibody has been shown to recognize active MEKK1 [15,23].
The CaspACE 3 assay was obtained from Promega (Madison,
WI). FITC secondary antibodies were purchased from Caltag
(Burlingame, CA) and Texas red-phalloidin from Molecular
Probes. The goat anti-rabbit IgG horseradish peroxidase was
obtained from (Santa Cruz Biotechnology, Inc).
Cell culture and transfections
HEK 293T cells were maintained with Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 IU/ml penicillin, and 100 mg/ml streptomycin.
Transient transfections were performed using FuGENE 6
according to the manufacturer instructions. DT40 and murine B
cell lines were maintained in DT40 medium (RPMI 1640 medium
containing 10% FBS, 1% chicken serum, 50 mM 2-mercaptoeth-
anol, 50 U of penicillin per ml, and 50 mg of streptomycin per ml)
at a density of 0.5610
6 to 1.5610
6 cells/ml. HeLa cells were
maintained in DMEM with 5% FBS and 100 IU/ml penicillin
and 100 mg/ml streptomycin.
Creation of murine B cell line
A murine stem cell virus vector containing the BCR-Abelson
fusion gene and GFP was transfected with helper virus plasmid
into HEK 293T cells, and supernatant was harvested after
36 hours. The filtered supernatant was used to infect bone marrow
cells from either wild type or MEKK1-deficient mice from the lab
of Bing Su. After approximately three weeks B cell populations
arose and clones were selected, as previously described [38].
MEKK1
2/2 reconstitution
Viral transduction was used to reconstitute DT40 MEKK1-
deficient cells; briefly, HEK 293T cells were transfected with a viral
helper construct plus pBABEpuro containing the indicated MEKK1
construct, using standard calcium phosphate methods. MEKK1-
deficient cells were then infected with the filtered 293T cell
supernatants followed by selection with 0.4 mg/ml of puromycin.
Western blotting and immunoprecipitation
MEKK1 and MAPK western blotting was previously described
[2]. Briefly, 5610
6 cells were lysed in modified RIPA or lysed
directly in 16 SDS loading buffer. Samples were sonicated, and
25 mgo r7 5mg of protein were boiled in SDS loading dye and run
on a 10% or 7% polyacrylamide electrophoresis separating gel
respectively for MAPK or MEKK1. The protein was then
transferred onto nitrocellulose membrane and then probed with
the indicated antibody. For immunoprecipitation of DT40 cell
lines, 50610
6 cells were resuspended in lysis buffer (20 mM Tris-
Hcl pH 7.5, 150 mM NaCl, 1% Triton-X 100 and 2 mM EDTA
supplemented with protease inhibitors, 5 mM NaVO4 and 1 mM
NaF). Cells were sonicated and lysates were cleared by
centrifugation. 20 ml of HA-agarose beads were added to the
lysates and incubated overnight at 4uC. Samples were then washed
four times with lysis buffer, boiled in SDS loading buffer, run on
SDS-PAGE gel and protein was detected by anti-phosphorylated
or total MEKK1 antibody. For immunoprecipitation from
transiently transfected 293T cells, 20 ml of flag-conjugated beads
were added to cell lysates instead of HA-agarose beads.
Analysis of Apoptosis
DNA laddering assays were performed as previously described
[2]. Briefly, 3.75610
6 wild type DT40 or MEKK1-deficient cells
were treated with 1 mM vinblastine sulfate, 2 mg/ml cytochalasin
D or 90 nM okadaic acid and then processed as previously
described. Propidium iodide staining protocol was followed as
previously described [39]. In brief, cells were stimulated with
1 mM vinblastine sulfate, 2 mg/ml cytochalasin D or 90 nM
okadaic acid for the indicated time points, washed once with PBS
and resuspended in Nicoletti buffer (0.1% sodium citrate and 0.1%
Triton-X 100) and fluorescence intensity was analyzed via flow
cytometry. In the caspase 3 activity assay, 2610
7 cells treated for
the indicated times with 1 mM vinblastine sulfate, 2 mg/ml
cytochalasin D or 90 nM okadaic acid, were lysed in 50 mlo f
ice-cold cell lysis buffer containing 50 mM HEPES (pH 7.4),
100 mM NaCl, 0.1% 3-[(3-cholamidopropyl)-dimethylammonio]-
1-propanesulfonate (CHAPS), 1 mM dithiothreitol, and 0.1 mM
EDTA, flash frozen in an ethanol-dry ice bath, and stored at
280uC before use. Caspase 3 activity assay experiments were
performed as described in the Calbiochem protocol for colori-
metric caspase 3 substrate I (Ac-DEVD-pNA). A405 readings were
taken on a plate reader at four hour intervals.
Immunofluorescence
To assess MEKK1 localization, HeLa cells were used due to
superior surface adhesion and high transfection efficiency. HeLa
cells were grown on coverslips and transfected using FuGENE6
according to the standard protocol. Twenty four hours post
transfection cells were fixed with cold methanol for three minutes
or 4% paraformaldehyde for 12 minutes, washed 3 times with PBS
and then permeabilized with 0.1% Triton-X 100 in PBS for
3 minutes. Primary antibodies were used at a 1:300 dilution in PBS
with 3% BSA overnight at 4u and washed 3 times with PBS for
5 minutes. Secondary antibodies were conjugated to either FITC or
TRITC and used at a dilution of 1:1000 in PBS with 3% BSA.
CIP treatment
DT40 cells were treated with 1 mM vinblastine for six hours and
cells were lysed in modified RIPA. MEKK1 was immunoprecip-
itated with 4 mg aMEKK1C-22 and 40 ml protein G sepharose
beads. Beads were resuspended in NEB buffer 3 with or without
calf alkaline phosphatase and incubated for one hour at 37uC.
SDS loading buffer was added and reactions run on SDS-PAGE.
Membranes were probed with aMEKK1.
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